GlassScriptPhysician profile
Silver Festin
NPI 1770259715
$3,521.83
in general payments reported to CMS, 2019-2025
43 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $796 · 2023: $2,568 · 2024: $20.54 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,463 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,462.95 |
| Education | $262.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $294.79 | 2022-2023 | Calquence, Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $236.52 | 2022-2023 | Injectafer, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $216.52 | 2022-2023 | Iclusig, Ninlaro |
| Incyte Corporation | $205.44 | 2022-2023 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $160.62 | 2022-2023 | |
| Janssen Biotech, INC. | $148.24 | 2023 | Darzalex, Imbruvica |
| Pfizer INC. | $138.08 | 2022-2023 | |
| Celgene Corporation | $130.01 | 2022-2023 | Pomalyst, Reblozyl |
| Glaxosmithkline, LLC. | $121.07 | 2022-2023 | Zejula, Jemperli |
| Amgen INC. | $112.88 | 2022-2023 | Kyprolis, Nplate, Xgeva |
| Merck Sharp & Dohme LLC | $104.77 | 2022-2023 | Keytruda, Lynparza |
| Exelixis INC. | $99.22 | 2022-2023 | Cabometyx |
| Seagen INC. | $94.95 | 2023 | Adcetris, Tivdak, Tukysa |
| Lilly USA, LLC | $86.45 | 2022-2025 | Zepbound, Mounjaro, Retevmo |
| Cti Biopharma Corp. | $85.13 | 2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 | |
| Genzyme Corporation | $84.09 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $73.46 | 2022-2023 | Monoferric |
| Heron Therapeutics, INC. | $66.15 | 2022-2023 | Sustol |
| Morphosys, US INC. | $66.05 | 2022-2023 | Monjuvi |
| Eisai INC. | $60.71 | 2022-2023 | |
| Tersera Therapeutics LLC | $58.33 | 2022-2023 | Xermelo |
| Novo Nordisk INC | $57.58 | 2025 | Wegovy |
| Pharmacyclics LLC, An Abbvie Company | $51.11 | 2023 | Imbruvica, Epkinly |
| Kite Pharma, INC. | $50.12 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $49.06 | 2022-2023 | Libtayo |
| Astellas Pharma US INC | $48.10 | 2023 | Padcev |
| Puma Biotechnology, INC. | $46.39 | 2022-2023 | |
| Octapharma USA, INC. | $45.84 | 2023 | Panzyga, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Coherus Oncology, INC. | $45.56 | 2022-2023 | |
| G1 Therapeutics, INC. | $44.68 | 2023 | Cosela |
| Deciphera Pharmaceuticals INC. | $42.20 | 2023-2024 | Qinlock |
| Genmab U.S., INC. | $35.96 | 2023 | Epkinly |
| Mirati Therapeutics, INC. | $35.31 | 2023 | Krazati |
| Janssen Pharmaceuticals, INC | $35.05 | 2023 | Xarelto |
| Currax Pharmaceuticals LLC | $31.63 | 2025 | Contrave |
| Aveo Pharmaceuticals, INC. | $29.70 | 2022-2023 | Fotivda |
| Abbvie INC. | $28.61 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $28.22 | 2023 | Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.28 | 2023 | |
| Taiho Oncology, INC. | $24.29 | 2023 | |
| Array Biopharma INC | $21.89 | 2023 | Lorbrena, Xalkori, Braftovi |
| Spectrum Pharmaceuticals INC. | $14.78 | 2023 | Rolvedon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silver Festin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.